Prediagnostic selenium status, selenoprotein gene variants and association with breast cancer risk in a European cohort study

Hughes, DJ; Schomburg, L; Jenab, M; Biessy, C; Méplan, C; Moskal, A; Sun, Q; Demircan, K; Fedirko, V; Weiderpass, E; Mukhtar, M; Olsen, A; Tjønneland, A; Overvad, K; Schulze, M; Nøst, TH; Skeie, G; Olsen, KS; Ricceri, F; Grioni, S; Palli, D; Masala, G; Tumino, R; Pasanisi, F; Amiano, P; Perez-Cornago, A; Travis, R

Women's Health Collection

Journal article

Prediagnostic selenium status, selenoprotein gene variants and association with breast cancer risk in a European cohort study

Abstract:: Selenium (Se) may help prevent breast cancer (BC) development. Owing to limited observational evidence, we investigated whether prediagnostic Se status and/or variants in the selenoprotein genes are associated with BC risk in a large European cohort. Se status was assessed by plasma measures of Se and its major circulating proteins, selenoprotein P (SELENOP) and glutathione peroxidase 3 (GPX3), in matched BC case-control pairs (2208 for SELENOP; 1785 for GPX3 and Se) nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Single nucleotide polymorphisms (SNPs, n = 452) in 55 selenoprotein and Se metabolic pathway genes and an additional 18 variants previously associated with Se concentrations were extracted from existing genotyping data within EPIC for 1564 case-control pairs. Multivariable-adjusted logistic regression models were used to calculate the odds ratios (ORs) and 95 % confidence intervals (CIs) of the association between Se status markers, SNP variants and BC risk. Overall, there was no statistically significant association of Se status with BC risk. However, higher GPX3 activity was associated with lower risk of premenopausal BC (4th versus 1st quartile, OR = 0.54, 95 % CI: 0.30–0.98, Ptrend = 0.013). While none of the genetic variant associations (P ≤ 0.05) retained significance after multiple testing correction, rs1004243 in the SELENOM selenoprotein gene and two SNPs in the related antioxidant TXN2 gene (rs4821494 and rs5750261) were associated with respective lower and higher risks of BC at a significance threshold of P ≤ 0.01. Fourteen SNPs in twelve Se pathway genes (P ≤ 0.01) in interaction with Se status were also associated with BC risk. Higher Se status does not appear to be associated with BC risk, although activity of the selenoenzyme GPX3 may be inversely associated with premenopausal BC risk, and SNPs in the Se pathway alone or in combination with suboptimal Se status may influence BC risk.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Hughes, D. J., Schomburg, L., Jenab, M., Biessy, C., Méplan, C., Moskal, A., Sun, Q., Demircan, K., Fedirko, V., Weiderpass, E., Mukhtar, M., Olsen, A., Tjønneland, A., Overvad, K., Schulze, M., Nøst, T. H., Skeie, G., Olsen, K. S., Ricceri, F., … Travis, R. (2023). Prediagnostic selenium status, selenoprotein gene variants and association with breast cancer risk in a European cohort study. Free Radical Biology and Medicine, 209(Pt 2), 381–393.

MLA Style

Hughes, DJ, et al. “Prediagnostic Selenium Status, Selenoprotein Gene Variants and Association with Breast Cancer Risk in a European Cohort Study.” Free Radical Biology and Medicine, vol. 209, no. Pt 2, 2023, pp. 381–93.

Chicago Style

Hughes, DJ, L Schomburg, M Jenab, et al. 2023. “Prediagnostic Selenium Status, Selenoprotein Gene Variants and Association with Breast Cancer Risk in a European Cohort Study.” Free Radical Biology and Medicine 209 (Pt 2): 381–93.
Print